The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.
Dermatology Clinical Trials Unit
Phone: (314) 273-3897
Email: DermTrials@email.wustl.edu
EPIC: WU IM DERM CLINICAL TRIALS POOL
Currently Enrolling Trials
ATOPIC DERMATITIS
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. (MORPHEUS)
ClinicalTrials.gov Identifier: NCT05696392
CUTANEOUS T-CELL LYMPHOMA
Real World Observational Study of Poteligeo in Adult Patients with Mycosis Fungoides and Sezary Syndrome (PROSPER)
ClinicalTrials.gov Identifier: NCT05455931
HIDRADENITIS SUPPURATIVA
A Phase 3 Study to Evaluate the Efficacy and Safety of Povorcitinib (oral JAK-i) in Participants with Moderate to Severe Hidradenitis Suppurativa (HS) (STOP-HS2)
ClinicalTrials.gov Identifier: NCT05620836
A Phase 2, randomized, double-blind, placebo-controlled, parallel group, proof-of-concept study assessing the efficacy and safety of amlitelimab (SQ; anti-OX40L) in adult participants with moderate to severe Hidradenitis Suppurativa
ClinicalTrials.gov Identifier: NCT06118099
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib (oral JAK-i) in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
ClinicalTrials.gov Identifier: NCT05889182
A Phase 2 Multicenter, Open-Label Sub Study to Evaluate the Safety and Efficacy of Lutikizumab (SQ; anti-IL-1) in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa
ClinicalTrials.gov Identifier: NCT05139602
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart (SQ; anti CXC 1/2) in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
ClinicalTrials.govIdentifier:NCT06046729
SKIN CANCER
Phase IIa, Single-arm, Open-label, Clinical Trial of calcipotriene plus 5-fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients
ClinicalTrials.govIdentifier:NCT0569903
SUPPORTIVE ONCODERMATOLOGY
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (CLEER)